Shannon N. Westin, MD, MPH

Articles

Patient-Centered Approaches to Frontline Low-Grade Ovarian Cancer: Optimizing Treatment, Quality of Life, and Fertility Preservation

October 19th 2023

Expert perspectives from Shannon Westin, MD, MPH, FACOG, on frontline treatment options for patients with newly diagnosed low-grade serous ovarian cancer in the context of recent clinical trial data. Dr. Westin discusses optimizing treatment strategies while prioritizing quality of life and fertility preservation for patients.

Dr. Westin on Remaining Challenges in Endometrial Cancer

September 10th 2020

Shannon N. Westin, MD, MPH, discusses remaining challenges in endometrial cancer.

Dr. Westin on Novel Targets in Endometrial Cancer

May 12th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Dr. Westin on Novel Targets in Endometrial Cancer

May 11th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Dr. Westin on Advances Made With PARP Inhibitors in Ovarian Cancer

January 18th 2019

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

Dr. Westin on Emerging PARP Inhibitors in Ovarian Cancer

November 20th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.

Dr. Westin on PARP Resistance in Ovarian Cancer

October 9th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.